Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.70 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.61 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382008 | 1.00 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL13930989 | 1.00 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL19293447 | 1.00 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL25770244 | 0.97 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL138746 | 0.97 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL16377441 | 0.97 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL19579378 | 0.97 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL13561367 | 0.97 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL18744121 | 0.97 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL4362052 | 0.97 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3923901-B1 | NON-THERAPEUTIC ORAL USE OF A COMPOSITION FOR WHITENING AND/OR LIGHTENING THE SKIN COMPRISING CYSTINE AND GLUTATHIONE IN A CYSTINE-GLUTATHIONE RATIO RANGING FROM 1.5 TO 4 | BRETAGNE CHIMIE FINE (FR) | 2023-12-13 | — | — | EP | claimed |
| CN-116135229-A | Application of hypocrellin-containing derivative with both peri-position and 2-position being simultaneously substituted in preparation of photodynamic anti-tumor drugs | 中国科学院理化技术研究所 | 2023-05-19 | — | — | CN | claimed |
| US-11969494-B2 | Non-therapeutic oral use of a composition for whitening and/or lightening the skin comprising cystine and glutathione in a cystine-glutathione ratio ranging from 1.5 to 4 | BRETAGNE CHIMIE FINE (FR) | 2024-04-30 | — | — | US | disclosed |
| EP-3923901-B1 | NON-THERAPEUTIC ORAL USE OF A COMPOSITION FOR WHITENING AND/OR LIGHTENING THE SKIN COMPRISING CYSTINE AND GLUTATHIONE IN A CYSTINE-GLUTATHIONE RATIO RANGING FROM 1.5 TO 4 | BRETAGNE CHIMIE FINE (FR) | 2023-12-13 | — | — | EP | disclosed |
| EP-3923901-C0 | NON-THERAPEUTIC ORAL USE OF A COMPOSITION FOR WHITENING AND/OR LIGHTENING THE SKIN COMPRISING CYSTINE AND GLUTATHIONE IN A CYSTINE-GLUTATHIONE RATIO RANGING FROM 1.5 TO 4 | BRETAGNE CHIMIE FINE (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-20230320970-A1 | Skin Care Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4257113-A1 | SKIN CARE COMPOSITIONS COMPRISING VITAMIN E AND VITAMIN B3 | Colgate-Palmolive Company (US) | 2023-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320970-A1 | Skin Care Compositions | TTPA, NQO1, ADH4 | PTGS1 562/4885GSTK1 241/4885GLO1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.